别名 Adenocarcinoma of Prostate、Adenocarcinoma of prostate、Adenocarcinoma of prostate (disorder) + [19] |
简介 An adenocarcinoma arising from the prostate gland. It is one of the most common malignant tumors afflicting men. The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland. Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival. Several grading systems have been proposed, of which the Gleason system is the most commonly used. Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease. |
靶点 |
作用机制 HDAC抑制剂 |
原研机构 |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2024-04-24 |
靶点 |
作用机制 PSMA调节剂 [+1] |
在研机构 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2023-05-25 |
靶点 |
作用机制 PSMA抑制剂 [+1] |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2022-03-23 |
开始日期2025-09-01 |
申办/合作机构 |
开始日期2025-04-15 |
申办/合作机构 |
开始日期2025-01-15 |
申办/合作机构 |